Sage Therapeutics, Inc.
SAGE
$6.75
$0.192.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 7.89% | 7.96% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 9.73% | 7.96% | |||
| Cost of Revenue | -57.49% | 1.30% | |||
| Gross Profit | 77.87% | 0.56% | |||
| SG&A Expenses | 5.39% | 2.68% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.04% | -17.61% | |||
| Operating Income | 16.68% | 20.61% | |||
| Income Before Tax | 35.04% | -2.38% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 35.04% | -2.38% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 35.04% | -2.38% | |||
| EBIT | 16.68% | 20.61% | |||
| EBITDA | 16.68% | 20.54% | |||
| EPS Basic | 35.67% | -2.14% | |||
| Normalized Basic EPS | 17.34% | 21.17% | |||
| EPS Diluted | 35.67% | -2.14% | |||
| Normalized Diluted EPS | 17.34% | 21.17% | |||
| Average Basic Shares Outstanding | 0.97% | 0.24% | |||
| Average Diluted Shares Outstanding | 0.97% | 0.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||